BRPI0906404A2 - construções de fusão com dominio lítico e processos de produção e de utilização das mesmas - Google Patents

construções de fusão com dominio lítico e processos de produção e de utilização das mesmas

Info

Publication number
BRPI0906404A2
BRPI0906404A2 BRPI0906404A BRPI0906404A BRPI0906404A2 BR PI0906404 A2 BRPI0906404 A2 BR PI0906404A2 BR PI0906404 A BRPI0906404 A BR PI0906404A BR PI0906404 A BRPI0906404 A BR PI0906404A BR PI0906404 A2 BRPI0906404 A2 BR PI0906404A2
Authority
BR
Brazil
Prior art keywords
lithic
domain
production
use processes
fusion constructions
Prior art date
Application number
BRPI0906404A
Other languages
English (en)
Inventor
Carola Leuschner
Hector Alila
Original Assignee
Univ Louisiana State
Esperance Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0906404(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Louisiana State, Esperance Pharmaceuticals filed Critical Univ Louisiana State
Publication of BRPI0906404A2 publication Critical patent/BRPI0906404A2/pt
Publication of BRPI0906404B1 publication Critical patent/BRPI0906404B1/pt
Publication of BRPI0906404B8 publication Critical patent/BRPI0906404B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C07K14/592—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH] at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
BRPI0906404A 2008-01-24 2009-01-26 construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno BRPI0906404B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2337708P 2008-01-24 2008-01-24
US61/023,377 2008-01-24
PCT/US2009/031999 WO2009094634A1 (en) 2008-01-24 2009-01-26 Lytic domain fusion constructs and methods of making and using same

Publications (3)

Publication Number Publication Date
BRPI0906404A2 true BRPI0906404A2 (pt) 2015-11-24
BRPI0906404B1 BRPI0906404B1 (pt) 2021-04-06
BRPI0906404B8 BRPI0906404B8 (pt) 2021-05-25

Family

ID=40671139

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906404A BRPI0906404B8 (pt) 2008-01-24 2009-01-26 construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno

Country Status (13)

Country Link
US (4) US8318899B2 (pt)
EP (1) EP2252627B1 (pt)
JP (1) JP5616233B2 (pt)
KR (2) KR101749310B1 (pt)
CN (1) CN102089320B (pt)
AU (1) AU2009206212B2 (pt)
BR (1) BRPI0906404B8 (pt)
CA (1) CA2713126C (pt)
DK (1) DK2252627T3 (pt)
ES (1) ES2633453T3 (pt)
IL (2) IL207181A (pt)
PT (1) PT2252627T (pt)
WO (1) WO2009094634A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031477A2 (en) * 2009-08-25 2011-03-17 Esperance Pharmaceuticals, Inc. Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same
US10093961B2 (en) 2009-12-22 2018-10-09 Esperance Pharmaceuticals Methods for diagnosis of and predicting treatment efficacy of hormone receptor expressing tumors, cancers and neoplasias
CN104177501A (zh) * 2010-02-09 2014-12-03 沈阳药科大学 蝎镇痛抗肿瘤缬精甘肽融合体及其获得方法
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
WO2012050892A2 (en) * 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
US8461118B2 (en) * 2011-07-07 2013-06-11 Tuskegee University Lytic peptides having anti-proliferative activity against prostate cancer cells
HUE044633T2 (hu) 2011-10-27 2019-11-28 Genmab As Heterodimer fehérjék elõállítása
PL397167A1 (pl) * 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
PL223487B1 (pl) * 2011-12-28 2016-10-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CA2870200A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP2910948B1 (en) 2012-10-17 2018-07-11 Public University Corporation Nara Medical University Novel cancer marker and utilization thereof
US9492563B2 (en) 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
CA2910311A1 (en) * 2012-11-15 2014-05-22 Esperance Pharmaceuticals, Inc. Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same
LT3200815T (lt) 2014-10-02 2021-07-26 The Wistar Institute Of Anatomy And Biology Būdai ir kompozicijos, skirti vėžio gydymui
GB2543550A (en) * 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
WO2017139644A1 (en) * 2016-02-12 2017-08-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Cancer treatment combination compositions, methods and uses
CN105963687A (zh) * 2016-04-27 2016-09-28 张金凤 一种用于治疗慢性盆腔疼痛的复方制剂及其制备方法
CN107955061B (zh) * 2017-11-15 2021-07-30 连云港恒运药业有限公司 地加瑞克关键中间体的制备方法
BR112022018994A2 (pt) * 2020-03-26 2022-11-29 A28 Therapeutics Inc Construtos de fusão de domínio lítico, inibidores de via de sinalização e métodos de produzir e usar os mesmos
CN112225821B (zh) * 2020-10-21 2021-05-21 徐州医科大学 一种具有抗肿瘤作用的多肽及其应用
CN118546212B (zh) * 2024-06-05 2024-12-20 中国海洋大学 一种抗胃肠道酶降解的高Fe2+结合活性肽及其应用
CN119331056B (zh) * 2024-09-25 2025-07-22 青岛大学 一种[Tyr3]Octreotate-D-构型溶瘤肽缀合物及其荧光探针的制备方法和应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327311C (en) * 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
US5861478A (en) * 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
ATE127838T1 (de) * 1987-07-06 1995-09-15 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
EP0514464A4 (en) 1990-02-08 1993-04-28 Magainin Sciences, Inc. Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell
US5792831A (en) * 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids
US5459237A (en) * 1990-02-08 1995-10-17 Magainin Pharmaceuticals Inc. Peptide compositions and uses therefor
WO1992022317A1 (en) 1991-06-12 1992-12-23 Magainin Pharmaceuticals, Inc. Composition and treatment with biologically active peptides having c-terminal substitutions
WO1993011783A1 (en) 1991-12-09 1993-06-24 Magainin Pharmaceuticals Inc. Composition and treatment with biologically active peptides and chelating agents
US6348445B1 (en) * 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
JPH08500818A (ja) 1992-06-01 1996-01-30 マガイニン ファーマシューティカルズ，インコーポレーテッド Ｎ末端置換を有する生物活性ペプチド
AU5081193A (en) * 1992-08-31 1994-03-29 Magainin Pharmaceuticals, Inc. Treatment of gynecological malignancies with biologically active peptides
WO1994012206A1 (en) 1992-12-03 1994-06-09 Magainin Pharmaceuticals, Inc. Treatment of dermatological malignancies with biologically active peptides
AU5741794A (en) 1992-12-07 1994-07-04 Magainin Pharmaceuticals, Inc. Treatment of septic shock with conjugated biologically active peptides
AU6251594A (en) 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors
EP0753071A1 (en) 1993-04-28 1997-01-15 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
WO1994028921A1 (en) * 1993-06-04 1994-12-22 Demeter Biotechnologies, Ltd. Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides
US5773413A (en) * 1993-06-04 1998-06-30 Demeter Biotechnologies, Ltd. Method of combating mammalian neoplasias, and lytic peptides therefor
US5955573A (en) * 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
US5968904A (en) * 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
AU1086595A (en) * 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
IL114697A0 (en) * 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
AU4602897A (en) * 1996-10-04 1998-04-24 Demegen, Inc. Method for treatment of immunodeficiency virus infection
WO2000053755A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
US6566334B1 (en) * 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
AU6587998A (en) 1997-03-27 1998-10-20 Demeter Biotechnologies, Ltd. Ligand/lytic peptide compositions and methods of use
US6635740B1 (en) * 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
AU8300598A (en) 1997-07-15 1999-02-10 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US6680058B1 (en) * 1997-09-03 2004-01-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for contraception in or sterilization of mammals
US6461813B2 (en) * 1998-09-21 2002-10-08 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in cell cycle regulation
PT1075277E (pt) * 1998-05-08 2009-05-08 Univ California Métodos para detectar e inibir a angiogénese
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
GB0005702D0 (en) 2000-03-09 2000-05-03 Alpharma As Method
BR0014198A (pt) 1999-09-23 2002-05-21 Zentaris Ag Processo para o gerenciamento terapêutico da proliferação extra-uterina de tecido endometrial, dor pélvica crÈnica e obstrução da tuba de falópio
ES2312435T3 (es) 2000-03-14 2009-03-01 Aeterna Zentaris Gmbh Antagonistas de lhrh, su preparacion y su uso como medicamentos.
JP2003534804A (ja) * 2000-05-30 2003-11-25 アイシーエイチ プロダクションズ リミテッド トランスフェクションの改良方法
US6875744B2 (en) * 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
WO2003041741A1 (en) 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Method of preventing or treating benign gynaecological disorders
DE60329382D1 (de) 2002-04-22 2009-11-05 Dow Global Technologies Inc Kostengünstige herstellung von peptiden
HRP20050371B1 (hr) 2002-09-27 2014-09-26 Zentaris Gmbh Oblik za primjenu farmaceutiski djelatnih peptida s produljenim oslobađanjem djelatnog sastojka i postupak za njihovu proizvodnju
EP1594519A4 (en) * 2002-11-15 2006-08-16 Sangstat Medical Corp CYTOMODULATION PEPTIDES FOR TREATING INTERSTITIAL CYSTITIS
CN1894277A (zh) 2003-02-24 2007-01-10 陶氏环球技术公司 周期性抗微生物肽
US7091185B2 (en) * 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
NO20031818D0 (no) 2003-04-23 2003-04-23 Uni I Tromsoe Fremgangsmåte av bioaktiv peptid forberedelse
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
GB0506759D0 (en) 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
US20090061006A1 (en) * 2006-03-31 2009-03-05 Carola Leuschner Layered Nanoparticles for Sustained Release of Small Molecules
US7288622B1 (en) * 2006-09-19 2007-10-30 Issar Pharmaceuticals Pvt Ltd Composition for treatment of burns and wounds
US7803755B2 (en) * 2006-12-21 2010-09-28 Jesse Jaynes Molecules for the treatment and prevention of fungal diseases

Also Published As

Publication number Publication date
US8318899B2 (en) 2012-11-27
JP2011517550A (ja) 2011-06-16
KR101863136B1 (ko) 2018-05-31
KR101749310B1 (ko) 2017-06-21
US8546535B2 (en) 2013-10-01
BRPI0906404B1 (pt) 2021-04-06
US20090233860A1 (en) 2009-09-17
CA2713126C (en) 2017-08-15
ES2633453T3 (es) 2017-09-21
KR20160106191A (ko) 2016-09-09
CA2713126A1 (en) 2009-07-30
AU2009206212B2 (en) 2014-01-16
DK2252627T3 (en) 2017-08-14
CN102089320B (zh) 2015-11-25
US9255134B2 (en) 2016-02-09
EP2252627A1 (en) 2010-11-24
IL243446B (en) 2021-08-31
US20090233861A1 (en) 2009-09-17
EP2252627B1 (en) 2017-04-19
AU2009206212A1 (en) 2009-07-30
US20090269341A1 (en) 2009-10-29
US20140255513A1 (en) 2014-09-11
KR20100127212A (ko) 2010-12-03
JP5616233B2 (ja) 2014-10-29
IL207181A0 (en) 2010-12-30
CN102089320A (zh) 2011-06-08
BRPI0906404B8 (pt) 2021-05-25
IL243446A0 (en) 2016-02-29
WO2009094634A1 (en) 2009-07-30
PT2252627T (pt) 2017-07-24
IL207181A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
BRPI0906404A2 (pt) construções de fusão com dominio lítico e processos de produção e de utilização das mesmas
BRPI1014404A2 (pt) cânula dotada de recurso de cânula e recurso de encaixe em sobreposição
BRPI0910482A2 (pt) imunoglobinas de domínio variável duplo e usos das mesmas
HRP20171612T2 (hr) Umrežujuće spojnice i njihova upotreba
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
BR112012002955A2 (pt) estruturas fibrosas e métodos de fabricação das mesmas.
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
PT3095452T (pt) Utilização de canabidiol em combinação com aripiprazol
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BRPI0924401A2 (pt) tradução de web com subustituição de exibição
PT2942355T (pt) Proteinas de fusao llo nao hemoliticas e utilizacoes das mesmas
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BR112012004710A2 (pt) imunoglobulinas de domínio variável duplo e uso das mesmas
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
EP2122054A4 (en) NONWOVEN PANEL AND PRODUCTION METHOD THEREOF
PT2483389T (pt) Estirpes de shigella com hipervesiculação
EP2267074A4 (en) RESIN COMPOSITION AND MULTILAYER CONSTRUCTION WITH RESIN COMPOSITION
FI20095084A0 (fi) Komposiitti ja sen käyttö
BRPI0918823A2 (pt) beta-glicosidases modificadas com estabilidades aperfeicoada
DK2280734T3 (da) Faktor-ix-konjugater med forlængede halveringstider
BRPI0910116A2 (pt) desvio transparente e mecanismos associados
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
DE112010001215A5 (de) Gurtaufrollersystem mit einsteuerglied
SMT201500273B (it) Diidroetorfine e loro preparazione
EP2435242A4 (en) CONSTRUCTION ELEMENT WITH SANDWICH STRUCTURE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF